2024-08-01
ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”) and Instil Bio, Inc. (Nasdaq: TIL, “Instil”), today announced a defin
View more
2024-07-03
First Patient In and Dosing completed in Phase III Clinical Trial of Timdarpacept (IMM01) combined with Tislelizumab for cHL patient refractory to PD-(L)1 therapy
On July 3, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that Timdarpacept (IMM01) combined with Tislelizumab for refractory cHL Phase III clinical trial successfully completed the first patient enrollment on July 1, 2024.
View more
2024-04-22
The Phase Ib clinical trial of IMM0306 in combination with lenalidomide for relapsed/refractory DLBCL completed the first patient enrollment
On April 22, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"), HKEX stock code: 01541.HK) announced that the Phase Ib clinical trial of IMM0306 in combination with len
View more
2024-04-18
Phase III clinical study of Timdarpacept combined with Tirellizumab for refractory cHL approved by CDE
On April 17, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as " ImmuneOnco "), HKEX stock code: 01541.HK) announced that the Phase III clinical study protocol of Timdarpacept (R&D number: IMM01) combined with Tirellizumab for PD-1/PD-L1 inhibitor failed Classic Hodgkin lymphoma (cHL) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
View more
